Megha Sinha, Kolter AI, discusses how pharma's AI bottleneck shifted from technology to readiness as execution across 60 markets stays manual. Access Part 1 of this interview on how digital twins run ...
Regulatory Optimisation Group efforts are converging on a future-state lifecycle change process, shifting from document-based ...
According to Schniepp, inspectors are not auditing the electronic submission mechanism itself because the eCTD system is ...
Megha Sinha, founder and CEO of Kolter AI and Kamet Consulting Group, spoke with PharmTech at the beginning of 2026 about her ...
A 2026–2027 joint work program operationalizes EMA–EISMEA cooperation to move European Innovation Council-funded projects ...
Neuland's Saharsh Davuluri revisits his December predictions for 2026, reporting steady progress on India manufacturing and AI adoption at midyear.
Novo Nordisk challenges nationwide Zepbound/Mounjaro advertising as misleading comparative promotion, citing omitted disclosure of the most effective FDA-approved semaglutide injectable doses. One ...
Greater accountability and resilience across drug development and manufacturing are key goals for regulators and industry.
A distributed “hub-and-spoke” operation could register as one establishment, reducing administrative friction while improving FDA visibility through required pre-notification of unit relocation and ...
Economic asymmetry after cartridge introduction drives a design philosophy centered on minimizing false acceptances and protecting API, with >99.5% first-pass yield as the principal success criterion.
Megha Sinha, Kolter AI, talks on how orchestrator roles surged in pharma AI, but teams need computed plans, not titles, to close the skills gap. Megha Sinha, Kolter AI, discusses how digital twins run ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results